Sinopharm Vaccine Falls Short on Antibodies in Budapest Study
A medical worker removes a box of the Sinopharm Group Co. Covid-19 vaccine from a refrigerator at a clinic in Budapest, Hungary.
Photographer: Akos Stiller/BloombergThis article is for subscribers only.
The Chinese-made Sinopharm vaccine has failed to produce sufficient antibodies in a quarter of elderly people who were voluntarily tested in Budapest, according to a study by the opposition-led Budapest City Hall.
The results were published just as Hungarian Prime Minister Viktor Orban’s government, which has faced opposition criticism for having widely adminsitered Sinopharm shots to older people, started offering third shots this week for anyone who requests them.